Rotavirus vaccines.
Rotavirus, the most common cause of severe diarrhea and a leading cause of mortality in children, has been a priority target for vaccine development for the past several years. The first rotavirus vaccine licensed in the United States was withdrawn because of an association of the vaccine with intussusception. However, the need for a vaccine is greatest in the developing world, because the benefits of preventing deaths due to rotavirus disease are substantially greater than the risk of intussusception. Early vaccines were based on animal strains. More recently developed and licensed vaccines are either animal-human re-assortants or are based on human strains. In India, two candidate vaccines are in the development process, but have not yet reached efficacy trials. Many challenges regarding vaccine efficacy and safety remain. In addition to completing clinical evaluations of vaccines in development in settings with the highest disease burden and virus diversity, there is also a need to consider alternative vaccine development strategies.
Kang
G
G
Department of Gastrointestinal Sciences, Christian Medical College, Vellore--632004, Tamilnadu, India. gkang@cmcvellore.ac.in
D000818:Animals; D002417:Cattle; D002986:Clinical Trials as Topic; D015195:Drug Design; D006801:Humans; D007443:Intussusception; D016865:Reassortant Viruses / Q000276:immunology; D012401:Rotavirus / Q000145:classification / Q000235:genetics / Q000276:immunology*; D012400:Rotavirus Infections / Q000517:prevention & control*; D022243:Rotavirus Vaccines / Q000008:administration & dosage / Q000009:adverse effects
D022243:Rotavirus Vaccines